Application and interpretation of free and total drug measurements in the development of biologics

Bioanalysis

Volumn 3, Issue 11, 2011, Pages 1287-1295

  Ahene, Ago B ^a  

^a XOMA Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3;

AREA UNDER THE CURVE; COMPLEMENTARITY DETERMINING REGION; DRUG DETERMINATION; DRUG HALF LIFE; HUMAN IMMUNODEFICIENCY VIRUS 1; LIGAND BINDING; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS ENTRY;

ANIMALS; CHEMISTRY TECHNIQUES, ANALYTICAL; DATA INTERPRETATION, STATISTICAL; DRUG DISCOVERY; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 79958715221     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.104     Document Type: Review

References (17)

1. Stoop JW, Zegers BJM, Sander PC, Ballieux RE. Serum immunoglobin levels in children and Adults. Clin. Exp. Immunol. 4, 101-112 (1968).
2. Giri JG, Wells J, Dower SK et al. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J. Immunol. 153, 5802-5809 (1994). (Pubitemid 24377716)
3. Lee JW, Kelley M, King LE et al. Bioanalytical approaches to quantify 'total' and 'free' therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS, 13(1), 99-110 (2011).
4. Kuang B, King L, Wang HF. Therapeutic monoclonal antibody concentration monitoring: free or total? Bioanalysis 2(6), 1125-1140 (2010).
5. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). S6: Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals CPMP/ICH/302/95 (1997).
6. European Medicines Agency. Guideline on requirements for first-in-man clinical trials for potential high-risk medicinal products. EMA, London, UK (2007).
7. Yang J, Ng C, Lowman H et al. Quantitative determination of humanized monoclonal antibody rhuMAb2H7 in Cynomolgus monkey serum using a generic immunoglobulin pharmacokinetic (GRIP) assay. J. Immunol. Met. 335(1-2), 8-20 (2008).
8. Stubenrauch K, Wessels U, Lenz H. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates. J. Pharm Biomed. Anal. 49(4), 1003-1008 (2009).
9. Chan D, Kim P. HIV entry and its inhibition. Cell 93 (5), 681-684, (1998). (Pubitemid 28257575)
10. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens and immunogens. Science 280(5371), 1884-1888 (1998). (Pubitemid 28299385)
11. Bruno CJ, Jacobson JM. Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection. J. Antimicrob. Chemother. 65(9),1839-1841 (2010).
12. Schellekens H. The immunogenicity of therapeutic proteins. Discov. Med. 9(49), 560-564 (2010).
13. Jones AT, Ziltener HJ. Enhancement of the biologic effects of interleukin-3 in vivo by anti-interleukin-3 antibodies. Blood, 82(4),1133-1141 (1993). (Pubitemid 23253986)
14. Patton A, Mullenix MC, Swanson SJ, Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J. Immunol. Met. 304, 189-195 (2005). (Pubitemid 41262233)
15. Davis RA, Butterfield AM, Konrad RJ, Bourdage JS. A novel method for quantitative measurement of a biomarker in the presence of a therapeutic monoclonal antibody directed against the biomarker. J. Pharm. Biomed. Anal. 48(3), 897-901 (2008).
16. Myler HA, McVay S, Kratzsch J. Troubleshooting PEG-hGH detection supporting pharmacokinetic evaluation in growth hormone deficient patients. J. Pharmacol. Toxicol. Met. 61(2), 92-97 (2010).
17. Verch T, Chilewski S, Bouaraphan S et al. Pharmacokinetic immunoassay methods in the presence of soluble target. J. Immunol. Met. 361, 75-81 (2010).